Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Front Endocrinol (Lausanne). 2022 May 30;13:859381. doi: 10.3389/fendo.2022.859381. eCollection 2022.
We collected 61 craniopharyngioma (CP) specimens to investigate the expression of TrkA, β-catenin, BRAF gene mutation, and NTRK1 fusion in CP. There were 37 male and 24 female individuals with a median age of 34 years (range, 4-75 years). Histologically, there were 46 cases of adamantinomatous craniopharyngioma (ACP), 14 cases of papillary craniopharyngioma (PCP), and 1 case with a mixed adamantinomatous and papillary pattern. By immunohistochemistry, we found that moderate/high TrkA expression was detected in 47% (28/60) CP and was significantly higher in adult patients (p = 0.018). Interestingly, TrkA is more expressed in "whorled epithelium" cells in ACP, similar to the localization of abnormal β-catenin. The abnormal expression rate of β-catenin was 70% (43/61), and the medium/high cyclin D1 expression rate was 73% (44/60), both of which were significantly higher in ACP than in PCP. Of the CP, 41% (21/51) had a moderate/strong P16-positive signal; 58% (34/59) showed a high Ki-67 expression, and there was a significant correlation between high Ki-67 L.I. and high tumor recurrence (p = 0.021). NTRK1 fusion was not found in CP by fluorescence hybridization (FISH). By PCR, 26% (15/58) CP showed BRAF V600E gene mutation, which mainly occurred in PCP (100%, 14/14) except one case of mixed CP. Moreover, TrkA expression was negatively correlated with Ki-67 index and positively correlated with P16 expression. There was a significantly negative correlation between BRAF V600E mutation and abnormal β-catenin expression. Our results demonstrate for the first time that TrkA expression might occur in CP, especially in adult CP patients, and suggest that cyclin D1 could be used for ACP histological classification in addition to β-catenin and BRAF V600E mutation, while Ki-67 could be used as a marker to predict CP recurrence.
我们收集了 61 例颅咽管瘤(CP)标本,以研究 TrkA、β-连环蛋白、BRAF 基因突变和 NTRK1 融合在 CP 中的表达。患者为 37 名男性和 24 名女性,中位年龄为 34 岁(范围 4-75 岁)。组织学上,有 46 例造釉细胞瘤型颅咽管瘤(ACP)、14 例乳头型颅咽管瘤(PCP)和 1 例混合造釉细胞瘤型和乳头型。通过免疫组织化学,我们发现 47%(28/60)的 CP 中存在中等/高 TrkA 表达,且在成年患者中表达更高(p=0.018)。有趣的是,TrkA 在 ACP 的“漩涡状上皮”细胞中表达更高,类似于异常β-连环蛋白的定位。β-连环蛋白异常表达率为 70%(43/61),中等/高 cyclin D1 表达率为 73%(44/60),ACP 均明显高于 PCP。在 CP 中,41%(21/51)有中等/强 P16 阳性信号;58%(34/59)表现出高 Ki-67 表达,高 Ki-67 LI 与高肿瘤复发显著相关(p=0.021)。荧光杂交(FISH)未发现 CP 中的 NTRK1 融合。通过 PCR,58%(15/58)CP 显示 BRAF V600E 基因突变,主要发生在 PCP(100%,14/14),除了 1 例混合 CP 外。此外,TrkA 表达与 Ki-67 指数呈负相关,与 P16 表达呈正相关。BRAF V600E 突变与异常β-连环蛋白表达呈显著负相关。我们的研究结果首次表明,TrkA 表达可能发生在 CP 中,特别是在成年 CP 患者中,并提示 cyclin D1 除了β-连环蛋白和 BRAF V600E 突变外,还可用于 ACP 的组织学分类,而 Ki-67 可作为预测 CP 复发的标志物。